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Sedated after Polytrauma 
Medical and Ethical Considerations 
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Background and Purpose: Heterotopic ossification (HO) often follows acetabular fractures after multitrauma. Irradiation is a 
mean for prophylaxis. We established a standard procedure in our hospital for patients under sedation, when obtaining informed 
consent for HO prophylaxis is impossible.
Patients and Methods: We reviewed current scientific evidence, calculated the risks of radiation and presented the ethical and 
legal framework. The subject was scrutinised by an interdisciplinary panel. 
Results: Irradiation is the most effective means for prophylaxis and has few adverse effects in adult patients with fractures of the 
acetabulum. The lifetime risk of radiation-induced cancer or infertility are insignificant. 
Conclusions: Informed consent for irradiation should be obtained before operation whenever possible. When this cannot be done 
prophylaxis can be postponed for a maximum of 3 days in order to obtain consent. If the patient is not able to communicate 
within this period, prophylactic irradiation should be given after consulting the relatives. The patient must be informed as soon 
as possible. 
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Prophylaxe heterotoper Ossifikationen bei sedierten Patienten nach Polytrauma. Medizinische und ethische 
Überlegungen 
Hintergrund und Ziel: Heterotope Ossifikationen (HO) entstehen häufig nach Acetabulumfrakturen. Übliche Methode der HO-
Prophylaxe ist die Bestrahlung. Ziel unserer Arbeit war die Erarbeitung einer standardisierten Vorgehensweise bei sedierten Pa-
tienten. 
Patienten und Methodik: Der medizinische Kenntnisstand, rechtliche und ethische Aspekte wurden zusammengetragen und 
Berechnungen für strahleninduzierte Risiken durchgeführt. Auf dieser Basis wurde die Thematik von einer interdisziplinären Ex-
pertengruppe diskutiert. 
Ergebnisse: Die Bestrahlung bei Patienten mit Acetabulumfraktur ist effektiv und risikoarm. Das Lebenszeitrisiko zur Entwicklung 
eines strahleninduzierten Malignoms ist gering. Es besteht kein Infertilitätsrisiko. 
Schlussfolgerungen: Ist die Zustimmung des Patienten zur prophylaktischen Bestrahlung präoperativ nicht einholbar und der 
Patient auch postoperativ nicht aufklärbar, werden Aufklärung und Bestrahlung bis drei Tage nach der Operation aufgeschoben. 
Ist der Patient weiterhin nicht aufklärbar, wird nach Rücksprache mit den Angehörigen die prophlyaktische Bestrahlung durchge-
führt. Die Aufklärung des Patienten wird baldmöglichst nachgeholt. 
Schlüsselwörter:  Heterotope Ossifikation · Prophylaktische Bestrahlung · Nicht steroidale Antiphlogistika (NSAI) · 
Acetabulumfraktur 
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Introduction 
In recent years, radiotherapy of certain non-malignant dis-
eases has experienced a remarkable comeback [9, 10, 24, 27, 
33]. In heterotopic ossification (HO), which typically follows 
fractures, dislocations or operative procedures, irradiation is 
an effective prophylactic. HO often affects the hip and may 
result in severe functional impairment in up to 50% of patients 
with major acetabular fractures [22, 23]. It is believed to result 
from inappropriate differentiation of pluripotential mesen-
chymal progenitor cells, which are either spread during trau-
ma or stimulated by immunological and inflammatory factors 
to form callus in situ [2]. Differentiation of mesenchymal cells 
occurs 16 hours after trauma and peaks at 36 hours [33]. Pro-
phylaxis is based on either local irradiation or non-steroidal 
anti-inflammatory drugs. 
In polytrauma patients, haemodynamic stabilisation and 
pain management are paramount – skeletal fixation has to be 
carefully timed. Acetabular fractures are mainly caused by 
high-energy trauma, frequently with further injuries requiring 
temporary sedation in an intensive care unit [15]. The best 
time for open reduction of acetabular fractures is 48 hours 
post-injury [17]. To guarantee optimal functional rehabilita-
tion, decisions are often needed before the patient can com-
municate. Informed consent, the basis of modern elective 
medicine, is often not an option and medical staff has to de-
cide according to the patient’s presumed wishes. 
Purpose and Method 
Following a case where a patient with multiple injuries was 
extubated briefly in order to give his informed consent to ra-
diotherapy, we realized that there was general uncertainty 
about the appropriate procedure for HO prophylaxis (Fig-
ure 1). In order to improve this unsatisfactory situation, we 
drew up a standard procedure for our hospital. Current 
scientific evidence about HO prophylaxis was collected. 
We calculated the specific risks and worked out a general 
framework for HO prophylaxis. The whole question was 
then considered by a panel of clinically-experienced radio-
oncologists and traumatologists, radiophysicists and clinical 
ethicists. 
Clinical and radiophysical evidence 
Incidence of HO 
HO is a major complication affecting the hip after arthroplasty 
(THA), traumatic acetabular fracture or central nervous in-
jury, with a peak incidence 6–12 weeks after the trauma. Mi-
nor HO consists of small ossification islands and is generally 
asymptomatic. Grades III and IV (Brooker’s scale), however, 
are characterised by severely impaired leg movements and 
complete ankylosis, respectively [7, 13]. 
Clinically relevant Grade III/IV HO after central nervous 
injury, caused only by inflammatory/immunological factors, is 
rare: the incidence is about 2–5%. In contrast, the figure is 
10% after THA, 20% after acetabular fractures, and up to 
50% in patients with severe trauma, pre-existing HO or addi-
tional CNS injury [11]. 
Effectiveness and risks of HO prophylaxis alternative 
Besides radiotherapy prevention of HO is based on non-steroi-
dal anti-inflammatory drugs (NSAIDs), the effectiveness of 
which has been studied extensively in patients with THA [23]. 
A few retrospective analyses on NSAIDs also showed a 
significant decrease of HO after indomethacin in patients un-
dergoing surgery for acetabular fractures [12, 19, 21]. How-
ever, Matta et al. terminated a prospective study on similar 
patients before statistical significance could be reached, be-
cause HO occurred in 27/50 patients on indomethacin and in 
25/44 without therapy [18]. They concluded that indometha-
cin was not sufficiently effective. A problem in interpreting 
results is that the duration, dosage and type of medication 
vary considerably amongst published studies on NSAID pro-
phylaxis [16].
Most important adverse effects of NSAIDs are gastroin-
testinal complications, including haemorrhage and perforated 
gastric ulcer. Pakos reviewed seven randomised studies com-
paring NSAIDs with radiotherapy in HO prophylaxis [23] and 
found gastrointestinal toxicity with discontinuation of NSAIDs 
in 4.6% of patients. However, in one of only two prospective 
studies on patients with acetabular fractures (rather than elec-
tive THA), complications causing discontinuation of medica-
tion were observed in 20% patients, including two life-threat-
ening gastrointestinal complications. Similarly, Karunakar et 
al. had to terminate a prospective investigation on acetabular 
fracture early, because of serious gastrointestinal complica-
tions in two patients and poor compliance in the indomethacin 
group [14].
NSAID have also been reported to increase the risk of 
long bone non-union [4] with a rate of 26% vs. 7% in irradiat-
ed patients or those without prophylaxis [6]. After radiothera-
py no increased risk of prosthesis instability or fracture heal-
ing disturbances has been observed [29]. 
Figure 1. 34-year old polytrauma patient with acetabular fracture. 
Abbildung 1. 34-jähriger Polytraumapatient mit Acetabulumfraktur. 
Oertel S, et al. Prophylaxis of Heterotopic Ossification in Sedated Patients
214 Strahlenther Onkol 2008 · No. 4  © Urban & Vogel
In contrast to NSAIDs, the effectiveness, timing and dose of 
radiotherapy as HO prophylaxis has been demonstrated in pa-
tients with acetabular fractures – the evidence is just as good as 
in patients treated for THA [1, 5, 8, 20, 25, 31, 34]. A single dose 
of 7–8 Gy (J/kg) is usually given. Higher doses have not proved 
superior and lower doses seem less effective [23]. Prophylactic 
irradiation can be given between 8 hours before and 72 hours 
after surgery, without diminishing its effectiveness [5, 28, 29]. 
In direct comparisons, six retrospective randomised stud-
ies showed NSAIDs to be slightly less effective then radio-
therapy in patients receiving prophylactic therapy with THA 
[23]. Burd compared postoperative 8 Gy single-dose radio-
therapy with a 6-week course of indomethacin (25 mg tds) in a 
prospective randomised study including patients with acetab-
ular fractures. He reported 11% severe HO in the indometha-
cin group and 4% in the radiotherapy group, against 38% in 
untreated patients [3]. However, his data lack statistical sig-
nificance because of the small number of patients. 
Adverse effects of radiotherapy – specific risk 
calculations 
Inducing malignancy is the most important fear of radiothera-
py. Radiation-induced leukaemia may occur within 2–30 years, 
with a peak after 5 years, while the risk of solid tumors in-
creases steadily after exposure [25, 34].
To assess these risks after HO prophylaxis, we calculat-
ed the dose distribution of typical hip irradiation in CT-slices 
of the Zubal Phantom. The phantom was manually segment-
ed as a computerised 3-D volume array, modelling all major 
internal structures [35]. The 3-D cube was reconstructed in a 
512 × 512 matrix with a resolution of 1 mm (x, y plane)/
10 mm (a z-axis). Each voxel was given an index number in-
dicating the organ or internal structure to which it belonged. 
We used the Eclipse External Beam Planning system (Vari-
an Oncology Systems, Palo Alto, CA), version 6.5, for treat-
ment planning with corrected dose distributions for head-, 
phantom- and collimator-scatter also including the extremi-
ties. All treatment plans were calculated with 6 MV photons 
and consisted of two opposed 14 × 17 cm fields, shaped by 
MLC to protect pelvic structures. We used isocentric anteri-
or-posterior (ap/pa) opposed fields to ensure dose homoge-
neity. The prescribed dose was 8.0 Gy. The organ equivalent 
dose (OED) distribution was obtained using a linear-expo-
nential and a plateau dose-response relationship for radia-
tion-induced cancer [26, 35]. To obtain the cumulative risk 
for solid cancer or for leukaemia as a function of age, for a 
patient irradiated at the age of 30, the OED averaged over 
the whole body and specifically in bone marrow was inte-
grated with respective survival function and mortality rates 
of the general population. 
Our calculations resulted in average OEDs of 0.28 Gy for 
the linear-exponential model and 0.26 Gy for the plateau 
dose-response model. The corresponding figures in bone mar-
row were 0.56 Gy and 0.52 Gy. Assuming irradiation for HO 
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Figure 2. Cumulative risk of a patient irradiated at the age of 30 devel-
oping a solid cancer, estimated with a linear-exponential model (bro-
ken line) and a plateau model (solid line). For comparison, the dotted 
line shows the risk of spontaneously developing cancer in the general 
population. 
Abbildung 2. Kumulatives Risiko für einen 30-jährigen Patienten, als 
Folge der Bestrahlung ein solides Karzinom zu entwickeln, geschätzt 
mittels eines linear exponentialen Modells (gestrichelte Linie) sowie 
eines Plateaumodells (durchgezogene Linie). Zum Vergleich ist das Ri-
siko der Allgemeinbevölkerung, spontan ein Karzinom zu entwickeln, 
als gepunktete Linie aufgeführt. 
Figure 3. Cumulative risk of a patient irradiated at the age of 30 devel-
oping leukaemia, estimated with a linear-exponential model (broken 
line) and a plateau model (solid line). For comparison, the dotted line 
shows the risk of spontaneously developing leukaemia in the general 
population. 
Abbildung 3. Kumulatives Risiko für einen 30-jährigen Patienten, als 
Folge der Bestrahlung eine Leukämie  zu entwickeln, geschätzt mittels 
eines linear exponentialen Modells (gestrichelte Linie) sowie eines 
Plateaumodells (durchgezogene Linie). Zum Vergleich ist das Risiko 
der Allgemeinbevölkerung, spontan eine Leukämie zu entwickeln, als 
gepunktete Linie aufgeführt. 
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prophylaxis at age of 30, the corresponding cumulative risks 
were plotted against age. Figure 2 shows the cumulative risk of 
all solid cancers for linear-exponential and plateau models. 
Figure 3 gives the plot for leukaemia. 
It can be seen that the additional risk of developing a ra-
diation-induced solid cancer increases with age, from 0.3% at 
50 to around 1% at 65. This increase must be viewed in rela-
tion to the risk of developing cancer spontaneously – 9.5% at 
age 65 in the general population, compared with 10.5% for ir-
radiated patients. 
The risk of developing leukaemia peaks a few years after 
irradiation and decreases thereafter. The cumulative risk of 
irradiated patients is therefore increased for a short time after 
treatment but is more or less constant for the rest of their lives. 
The cumulative risk at 65 is 0.80% for irradiated patients, 
compared to about 0.43% in the general population. 
In summary, lifetime risk of radia-
tion-induced malignancies after radio-
therapy to prevent HO is approximately 
1%, assuming conservative factors. The 
corresponding OED is equivalent to an 
effective dose of 50 mSv from low dose 
diagnostic applications. A typical ab-
dominal CT results in an effective dose 
of approximately 10 mSv, so the poten-
tial harm from hip irradiation with a 
dose of 8 Gy is five times that of one ab-
dominal CT scan.
We assessed oligospermia after HO 
prophylaxis using the Yale phantom to 
evaluate the average dose in the testes: 
this was 0.21 Gy. Younger men are usu-
ally given additional lead shielding for 
the testes, reducing the dose received to 
approximately 0.1 Gy [12]. In otherwise 
healthy men, the spermiogram is im-
paired only after a testicular dose of at 
least 0.2–0.7 Gy and recovers within 9 
weeks. Permanent effects on fertility are 
not seen with less than 1.2 Gy [32]. 
In women, radiation may cause in-
determinate damage to the ipsilateral 
ovary but, with a scattering dose of ap-
proximately 0.2 Gy and adequate pelvic 
shielding, reduced fertility is of no con-
cern. 
In contrast to all other radiation-in-
duced adverse effects, no threshold dose 
exists for the occurrence of radiation-in-
duced malignancies and genetic effects. 
Men should therefore be told not to fa-
ther children in the nine weeks following 
radiotherapy, to prevent fertilisation by 
genetically damaged sperm. As geneti-
cally damaged eggs usually do not ovulate, contraception for a 
specified period is unnecessary for women. 
Legal and ethical considerations 
Art. 13 of the 2005 Patient Law of the Canton of Zurich [36], 
requires that “medical staff have to meet their responsibility 
by informing patients in due time, properly and comprehen-
sively about the pros and cons of the recommended therapy 
and of any possible alternatives.” However, it is easy to obtain 
informed consent  in elective orthopaedic surgery, but tends to 
be more difficult in traumatology. 
Trauma patients usually need emergency surgery and are 
often on intensive care/ventilation afterwards. The question 
then arises how Art. 21 of the Zurich Patient Law should be 
applied: “If a patient is incapacitated and does not have a legal 
guardian, the attending doctors have to decide in the patient’s 
Patient in need of HO 
prophylaxis
Information before 
operation possible?
Yes
Patient decides in 
advance
Patient  
capable of making 
decisions after 
operation?
No
Patient 
expected to regain 
decisional capacity within 
3 days of
operation?
Irradiation 
(preferred)
or NSAID or refusal 
of HO prophylaxis Patient decides after 
operation
Decision delayed until 
patient regains 
decisional capacity
Irradiation as a rule
(after discussion with 
relatives)
Patient personally 
informed jointly by 
surgeon and radio-
oncologist as soon as 
possible
No
Yes
Yes No
Figure 4. Flow chart of the proposed procedure. Decision-making process in heterotopic ossifi-
cation (HO) prophylaxis. 
Abbildung 4. Flussdiagramm des vorgeschlagenen Prozederes. Entscheidungsprozesse bei der 
Prophylaxe heterotoper Ossifikationen (HO). 
Oertel S, et al. Prophylaxis of Heterotopic Ossification in Sedated Patients
216 Strahlenther Onkol 2008 · No. 4  © Urban & Vogel
best interest and according to his/her presumed will. If pos-
sible, relatives will be heard. Consent can be assumed in emer-
gency situations.” Art. 14 also has to be considered: “If the 
information cannot be given prior to the decision, this has to 
be rectified as soon as possible.” 
The situation is particularly delicate for radiotherapy; ra-
diooncologists find that, despite medical evidence, many pa-
tients still have strong reservations about radiotherapy or as-
sociate it with cancer therapy. Therefore, although the 
evidence clearly shows irradiation is superior to NSAIDs to 
prevent HO after acetabular fractures, the ethical and legal 
needs to obtain informed consent for the proposed prophy-
laxis remain.  
Discussion 
All the points mentioned above were discussed during the 
multidisciplinary panel from the radiooncological, physical, 
ethical, legal and orthopaedic points of view. 
For the above mentioned reasons the panel concluded 
that radiotherapy is the recommended mean for HO prophy-
laxis. 
The panel agreed that it is essential for patients and their 
families to be informed comprehensively and considerately, as 
soon as possible. However, members gave little support to the 
option of letting the patient wake from coma in order to ob-
tain informed consent: firstly, because the effects of sedatives 
may place in question the validity of the consent obtained and, 
secondly, because the arousal itself is risky. Instead, the panel 
developed following differentiated procedure (Figure 4). 
In elective situations, the option should be discussed with 
the patient preoperatively. When this cannot be done, radio-
therapy should be discussed with the patient immediately af-
ter operation. If this is still not possible the decision may be 
postponed up to three days post-surgery. If the patient is not 
expected to regain decisional capacity within this period, ra-
diation can be given without the patient’s explicit consent, but 
is discussed with relatives whenever possible. Once patients 
are conscious, they have to be informed by the orthopaedic 
surgeon and the radiooncologist together about any radio-
therapy given. 
We considered only adult patients. In children radiation 
may damage the epiphyseal cartilage leading to retarded 
growth. The tolerance dose of epiphyses are age-dependent. 
While 4 Gy may impair growth under the age of 6 years, 8 Gy 
are probably fairly safe for 16-year-old girls and 18-year-old 
boys. If children between these ages are given less than 10 Gy, 
permanent damage affecting growth is unlikely but possible. 
This possibility has to be weighed carefully against the risk of 
HO, given that the growth remaining in the femur is 30% in a 
7-year-old and 15% in a 10-year-old, but only 1% in a 14-year-
old [30].  
Careful counselling of the parents is necessary. Whenever 
the risk-benefit ratio cannot be assessed, we recommend not 
giving radiotherapy to children.  
Conclusions 
Informed consent for irradiation as the preferred means of 
HO prophylaxis should be obtained before operation. If this 
cannot be done prophylaxis can be postponed up to three days 
to obtain consent. If patients are not to be extubated within 
this period, prophylactic irradiation should be given after con-
sultation with relatives. Patients must be informed about this 
as soon as possible. 
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